Through Tumor Related Microbial Biomarkers
Micronoma liquid biopsy technology interrogates the microbial signal to detect and predict cancer with clinical-grade accuracy.
Saving patient lives with a minimally-invasive, cancer screening test.
From a simple blood draw, microbial DNA may reveal who has cancer and which type, even at early stages When Gregory Poore was a freshman in college, his otherwise healthy grandmother was shocked to learn that she had late-stage pancreatic cancer. The condition was...
UCSD team, and Micronoma founders, publish Nature paper identifying nucleic acid-based, tumor-specific microbial signatures in the blood, suggesting a new diagnostic approach.
Microbiome analyses of blood and tissues suggest cancer diagnostic approach.
Systematic characterization of the cancer microbiome provides the opportunity to develop techniques that exploit non-human, microorganism-derived molecules in the diagnosis of a major human disease.
Humans and Microbes
Humans and microbes co-exist in a mutual beneficial relationship in our bodies. Microbes can be found naturally not only in our stools, but also in our mouths, tissues and even our blood.
The microbiome is the community of all the microbes—bacteria, fungi, protozoa and viruses—that live on and inside the human body.
Microbes and Cancer
Microbes are now known to be found in human tissues, including cancer tissues. Micronoma is going a step further and looking at microbial signatures that would be predictive of a tumor in circulating blood.
Micronoma can detect and distinguish microbes in blood and predict if a patient is cancer free or presenting a specific cancer type.
draw to collect samples
research, discovery, and
NEXT GEN SEQUENCING
Using genomic sequencing to
pipelines to decipher and
New cancer cases
worldwide each year
Cancer deaths each year,
most preventable with
Global liquid biopsy market
forecast for 2023*
Better Approach to Liquid Biopsy
A liquid biopsy is a test done on a sample of blood to look for circulating tumor cells (CTC) or DNA that is shed from the tumor. Liquid biopsies may help find cancer at an early stage.
However, CTCs and ctDNA are scarce, fragile, and heterogenous, which means they are difficult to detect and may be missed. Additionally, they may not be cancer-specific, as various cancers can share many types of alterations.
Traditional liquid biopsies focus on all tumor DNA in the blood to identify the small mutation markers linked to the cancer. Present at often less than 0.1%, ensuring the capture of these rare biomarkers is a difficult task. At Micronoma, we focus on the microbial DNA. With noise and complexity removed, established microbial signatures are enriched and more evident.
Dr. Sandrine Miller
Montgomery Pharm. D. Ph.D.
Founder, Board Member, President and CEO
Founder, Board Member, Chief Analytic Officer, Oncobiota™ Inventor
Rob Knight, PhD
Founder and Advisory Board, Oncobiota™ Inventor
Magda Marquet Ph.D.
Co-Founder, Ajinomoto Althea & AltheaDx. Former Chairman of the Board of Directors of UCSD Moores Cancer Center
Goodrich & Rosati
San Diego Angel Conference (SDAC)